Researchers Develop 'Universal' Nasal Spray Vaccine for COVID, Flu, and Allergies

Got story updates? Submit your updates here. ›

Researchers at Stanford Medicine have developed an experimental nasal spray vaccine that has been shown to protect mice against a wide range of respiratory viruses, bacteria, and allergens, including SARS-CoV-2, influenza, and house dust mites. The vaccine works by supercharging the lungs' own immune defenses rather than targeting specific pathogens, potentially offering long-lasting protection against multiple illnesses with just two doses.

Why it matters

A universal vaccine that can protect against COVID-19, the flu, and common allergies in a single nasal spray could transform medical practice and provide fast, convenient protection against both existing and future respiratory illnesses. This type of broad-spectrum treatment could reduce the need for multiple yearly shots and better prepare the public for potential future pandemics.

The details

The nasal spray vaccine developed by researchers at Stanford Medicine has been shown to protect mice against a variety of respiratory viruses, bacteria, and allergens. Unlike traditional vaccines that target specific pathogens, this treatment works by imitating the communication signals immune cells exchange during infection, supercharging the lungs' own defenses to keep them on alert for at least three months. The vaccinated mice also showed a much faster immune response, with protection kicking in within days rather than the two weeks it took for unvaccinated mice.

• The research findings were published on February 19, 2026 in the journal Science.
• Researchers estimate the treatment could be available for human use within 5-7 years with adequate funding.

What they’re saying

What’s next

Researchers must now adapt the treatment for use in humans and conduct further clinical trials to demonstrate its safety and efficacy before it can be approved for widespread use.